PHAT Logo

Phathom Pharmaceuticals, Inc. (PHAT) 

NASDAQ
Market Cap
$508.04M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
248 of 960
Rank in Industry
151 of 550

Largest Insider Buys in Sector

PHAT Stock Price History Chart

PHAT Stock Performance

About Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori …

Insider Activity of Phathom Pharmaceuticals, Inc.

Over the last 12 months, insiders at Phathom Pharmaceuticals, Inc. have bought $180,332 and sold $30.83M worth of Phathom Pharmaceuticals, Inc. stock.

On average, over the past 5 years, insiders at Phathom Pharmaceuticals, Inc. have bought $2.44M and sold $23.37M worth of stock each year.

Highest buying activity among insiders over the last 12 months: KARBE FRANK (director) — $198,168. Parikh Asit (director) — $81,248.

The last purchase of 12,500 shares for transaction amount of $99,084 was made by KARBE FRANK (director) on 2024‑12‑13.

List of Insider Buy and Sell Transactions, Phathom Pharmaceuticals, Inc.

2024-12-19SaleChief Operating Officer
1,118
0.0017%
$8.00$8,944-7.00%
2024-12-19SaleCFO and CBO
1,291
0.0019%
$8.00$10,328-7.00%
2024-12-13Purchasedirector
10,000
0.0149%
$8.12$81,248+3.17%
2024-12-13Purchasedirector
12,500
0.0182%
$7.93$99,084+3.17%
2024-07-15SalePresident and Chief Executive
33,848
0.0663%
$11.72$396,6990.00%
2024-07-15SaleChief Operating Officer
10,901
0.0214%
$11.72$127,7600.00%
2024-07-15SaleCFO and CBO
4,325
0.0085%
$11.72$50,6890.00%
2024-04-08SaleCFO and CBO
3,435
0.0059%
$11.10$38,129-1.44%
2024-03-22SalePresident and Chief Executive
16,851
0.0238%
$9.11$153,513-1.27%
2024-01-24Sale10 percent owner
3.7M
7.8033%
$8.10$30M+55.90%
2024-01-19SaleCFO and CBO
6,307
0.0114%
$7.75$48,900+39.84%
2023-11-20SaleCFO and CBO
2,127
0.0037%
$7.24$15,403+37.99%
2023-11-08Purchasedirector
2,500
0.0044%
$7.80$19,500+30.93%
2023-11-07Purchasedirector
4,000
0.0067%
$7.76$31,040+25.00%
2023-11-06Purchasedirector
1,000
0.0018%
$8.04$8,040+28.13%
2023-11-01SaleCFO and CBO
12,492
0.0202%
$8.88$110,871+5.52%
2023-06-02SaleCFO and CBO
1,960
0.0045%
$11.41$22,368-13.46%
2023-05-22SaleCFO and CBO
2,110
0.0048%
$12.87$27,165-24.78%
2023-04-11PurchaseChief Operating Officer
10,000
0.0243%
$8.26$82,600+26.97%
2023-04-10Purchasedirector
1,000
0.0023%
$7.55$7,550+29.28%

Insider Historical Profitability

38.59%
Curran TerriePresident and Chief Executive
377734
0.5524%
$7.4326+28.29%
Nabulsi AzmiChief Operating Officer
239303
0.35%
$7.43215+23.01%
Henderson MollyCFO and CBO
98156
0.1436%
$7.43111
Parikh Asitdirector
75500
0.1104%
$7.4380+33.82%
KARBE FRANKdirector
57000
0.0834%
$7.4310

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Frazier Life Sciences Management L P$107.36M17.2710.11M0%+$04.85
Medicxi Growth I Lp$79.27M12.757.46M+98.48%+$39.33M17.65
The Carlyle Group$37.1M5.973.5M0%+$01.59
Invesco$33.56M5.43.16M-0.25%-$83,515.680.01
BlackRock$29.16M4.692.75M+2.48%+$706,113.17<0.01
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.